Pyrimidine derivatives used as PI-3 kinase inhibitors

US8563549B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Matthew Burger · Belmont, US
• Zhi-Jie Ni · Emeryville, US
• Sabina Pecchi · Oakland, US
• Gordana Ataliah · Emeryville, US
• Sarah Bartulis · Emeryville, US
• Kelly Frazier · Emeryville, US
• Aaron Smith · Fremont, US
• Joelle Verhagen · Emeryville, US
• Yanchen Zhang · Kensington, US
• Allan S. Wagman · Belmont, US
• Simon Ng · Walnut Creek, US
• Keith B. Pfister · Emeryville, US
• Daniel Poon · Piedmont, US
• Alicia Louie · Emeryville, US
• Teresa E. Pick · Danville, US
• Paul A. Barsanti · Emeryville, US
• Edwin J. Iwanowicz · Cranbury, US
• Wendy J. Fantl · Emeryville, US
• Thomas Hendrickson · Emeryville, US
• Mark Knapp · Oakland, US
• Hanne Meritt · Emeryville, US
• Charles Voliva · Emeryville, US
• Marion Wiesmann · Emeryville, US
• Xiahua Xin · Emeryville, US

Key dates

• Filing date: May 14, 2012
• Grant date: Oct 22, 2013
• Expiry date: May 14, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.